Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq analysis after depletion of ALDH1A2 by enhancer blocking in Jurkat cells

ABSTRACT: RNA-seq analysis after depletion of ALDH1A2 by enhancer blocking in Jurkat cells

PROVIDER: PRJNA562523 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq analysis after depletion of ALDH1A2 by enhancer blocking in Jurkat cells

Project description:RNA-seq analysis was performed in a T-cell acute lymphoblastic leukemia cell line (Jurkat) to analyze gene expression changes after ALDH1A2 depletion.

2020-12-31 | GSE136416 | GEO

PolyA-sequencing in Jurkat cells upon CDK12 depletion.

Project description:PolyA-sequencing in Jurkat cells upon CDK12 depletion.

| PRJNA679028 | ENA

Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation [RNA-seq]

Project description:Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation [RNA-seq]

| PRJNA624138 | ENA

Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation

Project description:Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation

| PRJNA624133 | ENA

Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation [ChIP-seq]

Project description:Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation [ChIP-seq]

| PRJNA624051 | ENA

Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation [RNA-seq]

Project description:The androgen receptor (AR) antagonist darolutamide has very recently been approved for the treatment of non-metastatic castration resistant prostate cancer (PCa). Here we determined the genome-wide effects of darolutamide on cis-acting regulatory elements involved in androgen signaling with a focus on enhancer and super-enhancer (SE) regions. Darolutamide strongly depleted the AR from regulatory elements and abolished the AR transcriptional signaling. Using two different androgen-dependent PCa cell lines we identified genomic-regions with different affinities for the AR in androgen-stimulated, androgen-depleted and darolutamide-antagonized conditions. Altogether, our findings demonstrate that darolutamide is a potent AR antagonist blocking genome-wide AR signaling and AR enhancer activation. Further, we show a dynamic AR cistrome and concomitant adapting chromatin environment to varying conditions and identified regions with high AR affinity in cell lines and tissue samples.

2020-04-10 | GSE148397 | GEO

RNA-seq analysis in Jurkat cells

Project description:RNA-seq analysis was performed in Jurkat cells (T-cell lymphoblastic leukemia cell line).

2016-12-31 | GSE81712 | GEO

PolyA-sequencing in Jurkat cells upon CDK12 depletion.

Project description:We analyzed the 3' end of polyadenylated transcripts in Jurkat cells treated with either THZ531 (vs. DMSO) or the CDK12 degrader BSJ-4-116 (vs. BSJ-4-116NC).

2021-01-05 | GSE161650 | GEO

RNA-seq analysis in ARIEL knockdown Jurkat samples

Project description:RNA-seq of control, shARIEL Jurkat cells

2019-05-11 | GSE112077 | GEO

Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation [ChIP-seq]

2020-04-10 | GSE148358 | GEO